Skip Navigation Links
 Venue 
 تاریخ های مهم 
 Registration 
 Pre Registered 
 Abstracts 
 برنامه همایش 
 Exhibition 
 Personal page 
  
 Archive 
                             دومین ويژه نامه همايش بهاره چشم پزشكي منتشر شد        شب بهاری چشم پزشکی با رحیم شهریاری       دومین همایش بهاره چشم پزشکی
Skip Navigation Links
        مکان برگزاری
        تاریخ های مهم
        ثبت نام
        ثبت نام شدگان
        مقالات
        برنامه همایش
        نمایشگاه
        صفحه شخصی
        جستجوی سخنران
        آرشیو
 
مقاله Abstract


Title: Assessment of Dry Eye and Corneal Endothelial Cell Changes’ Prevalence Following 106Ru Plaque Brachytherapy for Intraocular Tumors: A Prospective Multiple Test Study
Author(s): Hossein Aghaei, Ahad Sedaghat, Masood Naseripour, Navid Abolfathzadeh, Amirpooya Alemzadeh
Presentation Type: Poster
Subject: Cornea & lens
Others:
Presenting Author:
Name: Navid Abolfath Zadeh
Affiliation :(optional) Eye Research Center, Rassoul Akram Hospital, Iran University of Medical Sciences, Tehran, Iran
E mail: navid.ab@gmail.com
Phone:
Mobile: 09127969425
Purpose:

This prospective was study designed to report the clinical outcomes of 106Ru plaque brachytherapy in ocular surface and cornea, with an emphasis to provide a framework for preventive strategies to reduce the radiation-related anterior segment complications.

Methods:

Twenty four patients diagnosed with intraocular tumors from 2015 to 2017, which were candidates for 106Ru plaque brachytherapy were included. The following tests were performed preoperatively, 1 week, 1 month, 3 month and 6 month postoperatively: Ocular Surface Disease Index (OSDI) questionnaire (validated Persian version), Tear osmolarity, Tear Break up Time (TBUT), Schirmer I, Oxford fluorescein staining and Specular microscopy test of cornea. Clinical features of tumors were also evaluated. Patients were divided to dry eye disease group (A) and non- dry eye disease group (B) based on their preoperative examinations. Dry eye was defined according to DEWS II Report 2017 and patients with moderate to severe dry eye were excluded from study.

Results:

Six of 11 patients (54.50%) and 5 of 13 patients (38.50%) were male in group A and B respectively (P=0.45). Mean age of patients was 46.23±16.26 and 51.81±14.57 in group A and B respectively (P=0.38). Total apex dose (Gy) was 82.50±27.50 and 84.10±27.70 in group A and B respectively (P=0.89). Total sclera contact dose (Gy) was 653.20±546.40 and 570.30±380.80 in group A and B respectively (P=0.68). In preoperative assessments, OSDI score was 31.30±10.30 and 0.30±1.20 in group A and B respectively (P=0.00), however other tests did not show significant difference between groups. At 6 month follow-up assessments, TBUT was 4.60±1.10 and 8.50±2.70 seconds in group A and B respectively (P=0.00), however other tests did not show significant difference between groups. At 6 month follow-up, endothelial cell density showed strong inverse correlation with total sclera contact dose (Pearson correlation= -0.77) (P=0.00).

Conclusion:

Patients may have dry eye disease before initiation of plaque brachytherapy. In patients with confirmed preoperative dry eye, 106Ru plaque brachytherapy does not deteriorate the ocular surface status significantly. However, it’s recommended to evaluate all patients scheduled for plaque brachytherapy preoperatively, to find subjects with increased susceptibility. OSDI could be an important tool to identify such susceptible patients.

Attachment: 53DED-Plaque-IRAVO 97 - version final.pptx





Last News

  - دومین ويژه نامه همايش بهاره چشم پزشكي منتشر شد
  -  شب بهاری چشم پزشکی با رحیم شهریاری
  - دومین همایش بهاره چشم پزشکی